OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Shah on Safety and Efficacy Outcomes With Obe-Cel in Older R/R ALL

August 21st 2025

Bijal Shah, MD, MS, discusses key safety and efficacy outcomes from a post hoc analysis of the FELIX trial of obe-cel in relapsed/refractory B-ALL.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Dr Wainberg on Treatment Updates in Gastric Cancer and Biliary Tract Cancer

August 21st 2025

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Dr Powles on the Role of the CREST Study in Future Clinical Trial Design in BCG-Naive NMIBC

August 21st 2025

Thomas Powles, MBBS, MRCP, MD, discusses how future clinical trials could leverage the CREST trial as a basis for BCG-naive NMIBC treatment development.

Dr Marshall on the Role of Fruquintinib in the Treatment Paradigm for mCRC

August 20th 2025

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

Dr Martini on the Clinical Significance of Nadofaragene Firadenovec in BCG–Unresponsive NMIBC

August 20th 2025

Alberto Martini, MD, discusses the current optimal role of nadofaragene firadenovec in the BCG-unresponsive NMIBC treatment paradigm.

Dr Chahoud on the Rationale for Evaluating Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

August 20th 2025

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

Dr Gupta on Updated Efficacy Data With Liso-Cel in Second-Line Relapsed/Refractory LBCL

August 19th 2025

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Dr Ku on the Rationale for Evaluating JNJ-90014496 in Relapsed/Refractory LBCL

August 19th 2025

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Dr Wang on Reducing Treatment Discontinuation in Older Patients With mCRPC

August 19th 2025

Jue Wang, MD, discusses the challenge of treatment discontinuation in older patients with metastatic castration-resistant prostate cancer.

Dr Randall on the Complexity of PEComas

August 19th 2025

R. Lor Randall, MD, FACS, discusses the complexity of perivascular epithelioid cell tumors and the critical importance of multidisciplinary care.

Dr Halmos on Selection Criteria for Adjuvant Therapy After Chemo/IO in NSCLC

August 19th 2025

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

Dr Jerkeman on the Importance of Recognizing the Biological Heterogeneity Within MCL

August 19th 2025

Mats Jerkeman, MD, discusses the importance of conducting further research to classify the biological heterogeneity within MCL.

Dr Gangat on Reducing JAK2 Allele Burden With Ruxolitinib or Ropeginterferon Alfa-2b in Polycythemia Vera

August 19th 2025

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Dr Vento on the Importance of Refining the Classification of RCC to Better Account for Molecular Heterogeneity

August 18th 2025

Joseph Vento, MD, discusses the importance of refining RCC classification standards to improve the field’s understanding of the disease’s heterogeneity.

Dr Mewawalla on Unmet Needs After Early CAR T-Cell Therapy in Relapsed/Refractory Myeloma

August 18th 2025

Prerna Mewawalla, MD, discusses needs that remain to be addressed in patients with relapsed/refractory myeloma who receive earlier-line CAR T-cell therapy.

Dr Mayadev on Using PD-L1 TAP as a Predictive Biomarker for Locally Advanced Cervical Cancer

August 18th 2025

Jyoti Mayadev, MD, discusses the clinical significance of tumor area positivityas a predictive biomarker in locally advanced cervical cancer.

Dr García-Carbonero on Outcomes With Fruquintinib in mCRC Subgroups

August 15th 2025

Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.

Dr Raza on Talquetamab Plus Teclistamab in R/R Myeloma and Extramedullary Disease

August 15th 2025

Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Dr Pemmaraju on Responses With Pivekimab Sunirine in Frontline and R/R CD123+ BPDCN

August 15th 2025

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.